MICHAEL WILLIAMS: Open Payments
NPI 1295706430 · LEES SUMMIT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,542 in 140 payments from 20 companies in 2025. Trend: 2023 $2,534 · 2024 $2,689 · 2025 $2,542
Food & beverage: $2,537Education: $5
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $489 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $465 |
| Teva Pharmaceuticals USA, Inc. | 21 | $275 |
| Janssen Pharmaceuticals, Inc | 17 | $250 |
| Vanda Pharmaceuticals Inc. | 7 | $177 |
| E.R. Squibb & Sons, L.L.C. | 8 | $151 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| Lundbeck LLC | 3 | $81 |
| Neurocrine BioSciences, Inc. | 4 | $77 |
Products named: VRAYLAR, CAPLYTA, AUSTEDO XR, REXULTI, FANAPT, SPRAVATO, COBENFY, INVEGA SUSTENNA.
Industry payments across MO — which companies pay providers there.
